IHC was performed to assess KMO expression in aretrospective cohort with 205 HCC patients, including 59 cases of stage I(28.8%), 120 cases of stage II (58.5%), and 26 cases of stage III (12.7%), basedon the TNM staging. This evidence concerns the gene KMO and hepatocellular carcinoma.